genOway
Designs and develops genetically modified preclinical models for research.
ALGEN | PA
Overview
Corporate Details
- ISIN(s):
- FR0004053510
- LEI:
- 969500HMHUPR3KYXUT19
- Country:
- France
- Address:
- 31 RUE SAINT JEAN DE DIEU, 69007 LYON
- Website:
- https://www.genoway.com
Description
genOway is a biotechnology company that specializes in designing and developing genetically modified preclinical models. It provides biopharmaceutical companies and academic researchers with genetically engineered mouse, rat, and cell line models intended to improve the predictability of preclinical research. The company's portfolio includes a catalog of off-the-shelf models as well as customized model creation services. Key areas of application for its models include immuno-oncology and pharmacokinetic (PK) analysis, featuring a range of humanized models. genOway emphasizes a collaborative approach, providing scientifically validated solutions to support the development of new therapies for clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-17 18:00 |
genOway crée une coentreprise à Shanghai avec pour objectif de devenir le parte…
|
French | 141.9 KB | ||
| 2023-09-21 18:00 |
Forte progression des résultats semestriels 2023 - Atteinte de l'objectif de re…
|
French | 207.3 KB | ||
| 2023-08-31 18:00 |
Nouvelle réussite technologique pour la gamme de modèles humanisés ICP de genOw…
|
French | 204.2 KB | ||
| 2023-07-18 07:30 |
Un 1er semestre 2023 dynamique porté par une progression de +36% de l''activité…
|
French | 186.0 KB | ||
| 2023-06-07 18:00 |
Nouveau succès commercial des modèles Catalogue en immuno-oncologie de genOway …
|
French | 199.4 KB | ||
| 2023-04-06 18:00 |
Résultats 2022 records : chiffre d'affaires en croissance organique de +22%, EB…
|
French | 204.7 KB | ||
| 2023-01-16 18:00 |
Chiffre d'affaires 2022 de 17,1 M EUR en croissance de +22% conforme aux object…
|
French | 187.4 KB | ||
| 2023-01-06 18:10 |
Bilan semestriel du contrat de liquidité
|
French | 323.2 KB | ||
| 2022-09-19 18:00 |
Forte progression des résultats semestriels 2022
|
French | 205.2 KB | ||
| 2022-09-14 18:00 |
SIGMA-ALDRICH et genOway élargissent leur alliance stratégique CRISPR/CAS9
|
French | 101.9 KB | ||
| 2022-07-18 19:00 |
Une croissance semestrielle de +26% avec une progression toujours aussi forte d…
|
French | 175.9 KB | ||
| 2022-05-23 18:00 |
Le Conseil d'administration de genOway propose la nomination d'Olivier Charmeil…
|
French | 173.0 KB | ||
| 2022-03-28 18:00 |
Résultats annuels 2021
|
French | 179.5 KB | ||
| 2022-01-31 18:00 |
Chiffre d'affaires 2021 en croissance de 27% conforme aux objectifs stratégique…
|
French | 167.3 KB | ||
| 2021-12-13 18:00 |
genOway licencie sa technologie CRISPR/Cas9 à l'agence nationale de financement…
|
French | 119.6 KB |
Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for genOway
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for genOway via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-17 | N/A | Other | Sell | 1,700 | 8,160.00 EUR |
| 2023-12-15 | N/A | Other | Sell | 5,000 | 22,000.00 EUR |
| 2023-11-23 | N/A | Other | Sell | 500 | 2,100.00 EUR |
| 2023-10-23 | N/A | Other | Sell | 100 | 390.00 EUR |
| 2023-09-25 | N/A | Other | Buy | 5,000 | 20,000.00 EUR |
| 2023-05-04 | N/A | Other | Buy | 60,000 | 222,000.00 EUR |
| 2023-05-02 | N/A | Other | Sell | 20,000 | 74,000.00 EUR |
Peer Companies
